Lost .I don’t think a lot of investors realize that .
1.That Acadia just needs to replicate the same results Neuren achieved in the Phase 2 results which were going for 6 weeks and continued to improve the longer they went .
2. Acadia has spent over $130 mill on Phase 3 trial so far .
3. The Phase 3 trials have been better targeted than the Phase 2 results .
4. Being an orphan drug the FDA is more receptive in getting the drug to market as at this stage there are no drugs available to help with retts syndrome .
2021, page-25
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.60 |
Change
-0.150(1.09%) |
Mkt cap ! $1.762B | |||
| Open | High | Low | Value | Volume |
| $13.85 | $14.08 | $13.46 | $3.520M | 257.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 497 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.62 | 338 | 9 |
View Market Depth
| Last trade - 12.58pm 10/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |